​

Contineum Therapeutics, Inc. Class A (CTNM) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

CTNM Stock Forecast

Contineum Therapeutics, Inc. Class A (CTNM) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $32.00, with a high of $32.00 and a low of $32.00. This represents a 209.18% increase from the last price of $10.35.

$10 $15 $20 $25 $30 $35 High: $32 Avg: $32 Low: $32 Last Closed Price: $10.35

CTNM Stock Rating

Contineum Therapeutics, Inc. Class A stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 2 Strong Sell Sell Hold Buy Strong Buy

CTNM Forecast vs Benchmarks

TypeNameUpside
StockContineum Therapeutics, Inc. Class A209.18%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$30.33
Last Closing Price$10.35$10.35$10.35
Upside/Downside--193.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2522---4
Dec, 2422---4
Nov, 2422---4
Oct, 2422---4
Sep, 2422---4
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024Joel BeattyRobert W. Baird$32.00$16.0799.13%209.18%
Apr 30, 2024Brian AbrahamsRBC Capital$30.00$16.0087.50%189.86%
Apr 30, 2024Paul MatteisStifel Nicolaus$29.00$16.0081.25%180.19%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024RBC CapitalOutperformOutperformhold
Apr 30, 2024Morgan StanleyOverweightinitialise
Apr 30, 2024RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.13-----
Avg Forecast-$-1.92$-1.81$-3.11$-3.27$-4.88
High Forecast-$-2.00$-1.84$-3.11$-3.27$-4.88
Low Forecast-$-1.82$-1.77$-3.11$-3.27$-4.88
Surprise %------

Revenue Forecast

$5M $14M $23M $32M $41M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.00M-----
Avg Forecast$50.00M$50.00M$7.50M$50.00M$50.00M$50.00M
High Forecast$50.00M$50.00M$7.50M$50.00M$50.00M$50.00M
Low Forecast$50.00M$50.00M$7.50M$50.00M$50.00M$50.00M
Surprise %------

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.72M-----
Avg Forecast-$-34.03M$-32.08M$-55.15M$-57.99M$-86.67M
High Forecast-$-35.55M$-32.76M$-55.15M$-57.99M$-86.67M
Low Forecast-$-32.34M$-31.39M$-55.15M$-57.99M$-86.67M
Surprise %------

CTNM Forecast FAQ

Is Contineum Therapeutics, Inc. Class A stock a buy?

Contineum Therapeutics, Inc. Class A stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Contineum Therapeutics, Inc. Class A is a favorable investment for most analysts.

What is Contineum Therapeutics, Inc. Class A's price target?

Contineum Therapeutics, Inc. Class A's price target, set by 2 Wall Street analysts, averages $32 over the next 12 months. The price target range spans from $32 at the low end to $32 at the high end, suggesting a potential 209.18% change from the previous close price of $10.35.

How does Contineum Therapeutics, Inc. Class A stock forecast compare to the average forecast of its sector, industry, and investment themes?

Contineum Therapeutics, Inc. Class A stock forecast shows a 209.18% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Contineum Therapeutics, Inc. Class A over the past three months?

  • January 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Contineum Therapeutics, Inc. Class A’s EPS forecast?

Contineum Therapeutics, Inc. Class A's average annual EPS forecast for its fiscal year ending in December is -1.92 for 2024, a -1576.92% decrease from the reported $0.13 in 2023. The prediction for 2025 is $-1.81, $-3.11 for 2026, $-3.27 for 2027, and $-4.88 for 2028.

What is Contineum Therapeutics, Inc. Class A’s revenue forecast?

Contineum Therapeutics, Inc. Class A's average annual revenue forecast for its fiscal year ending in December is $50M for 2024, a 0% decrease from the reported $50M in 2023. The forecast for 2025 is $7.5M, $50M for 2026, $50M for 2027, and $50M for 2028.

What is Contineum Therapeutics, Inc. Class A’s net income forecast?

For its fiscal year ending in December, Contineum Therapeutics, Inc. Class A's average annual net income forecast is $-34.029M for 2024, reflecting a -249.78% decrease from the reported $22.72M in 2023. The projection for 2025 is $-32.076M, $-55.147M for 2026, $-57.989M for 2027, and $-86.672M for 2028.